Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 9.6% from a year ago

Cash & equivalents stood at $27.59M at the end of Q1 FY2026, up 9.6% from a year earlier and up 31.7% from the prior quarter. Over 3 fiscal years it compounded at -40.7% a year.

Context

  • Cash & equivalents amounted to 46.0% of total assets at the end of Q1 FY2026, up 16.8 pp from a year earlier.
  • Cash & equivalents increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +9.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$27.59M+31.7% QoQ
Last fiscal yearDec 2025
$20.95M-50.0% YoY
Year agoMar 2025
$25.18M+9.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.6%——
1 year-50.0%——
3-year CAGR-40.7%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
20.95M USD
Year-over-year change
-50.0%
4-year CAGR
-41.5%

Cash & Equivalents vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +9.6% is the 6th highest of 11, against a peer median of +8.0%.
  • Cash & equivalents amounts to 46.0% of total assets for SGMO, versus a peer median of 32.7%.
SGMO Competitors
Cash & Equivalents for SGMO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IVVDInvivyd, Inc.Mar 2026$184.15M USD+283.0%+35.0%76.2%
MOLNMolecular Partners AGMar 2026CHF 78.53M CHF-3.5%-2.0%89.9%
MISTMilestone Pharmaceuticals Inc.Mar 2026$71.32M USD+58.2%+112.3%36.8%
CCCCC4 Therapeutics, Inc.Mar 2026$61.27M USD+19.5%+35.9%18.6%
CDXSCodexis, Inc.Mar 2026$37M USD+102.0%-23.6%28.6%
OABIOmniAb, Inc.Mar 2026$29.05M USD+166.7%-8.6%9.9%
IMDXInsight Molecular Diagnostics Inc.Mar 2026$28.2M USD-9.1%-16.6%69.8%
IPHAInnate Pharma S.A.Dec 2025€28.08M EUR-57.7%-30.7%44.8%
SGMOSangamo Therapeutics, Inc.Mar 2026$27.59M USD+9.6%-40.7%46.0%
RANIRani Therapeutics Holdings, Inc.Mar 2026$9.64M USD-4.6%-11.7%18.6%
ARMPArmata Pharmaceuticals, Inc.Mar 2026$4.75M USD-59.3%-16.4%6.8%
Peer median (excluding SGMO) —+8.0%-10.1%32.7%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents178.87M100.44M45.2M41.92M20.95M
Short-term Investments197.68M177.19M35.8M00
Net Receivables6.36M4.47M4.07M4.6M10.51M
Inventory00000
Other Current Assets009.26M5.18M4.37M
Total Current Assets398.77M300.33M94.33M51.69M35.83M
Property, Plant & Equipment (Net)124.7M125.53M52.87M34.76M14.11M
Goodwill39.7M37.55M000
Intangible Assets53.76M50.73M000
Long-term Investments88.17M29.85M1.5M1.5M0
Tax Assets06.27M000
Other Non-current Assets16.82M12.25M16.63M13.69M9.81M
Total Non-current Assets323.15M262.18M70.99M49.94M23.92M
Total Assets721.92M562.51M165.32M101.64M59.75M
Account Payables9.76M22.42M15.26M15.49M14.44M
Short-term Debt00000
Tax Payables0004.07M10.14M
Deferred Revenue85.71M51.78M07.56M899K
Other Current Liabilities20.84M11.89M11.73M14.57M17.72M
Total Current Liabilities127.89M111.71M47.73M45.81M42.47M
Long-term Debt00000
Deferred Tax Liabilities6.65M6.27M000
Deferred Revenue (Non-current)166.78M109.38M05.87M5.87M
Other Non-current Liabilities1.22M1.21M1.19M933K580K
Total Non-current Liabilities218.69M155.84M34.7M33.06M31.55M
Total Liabilities346.58M267.55M82.43M78.87M74.01M
Common Stock1.46M1.67M1.78M2.13M3.51M
Retained Earnings(956.27M)(1.15B)(1.41B)(1.5B)(1.63B)
Accumulated OCI(3.99M)(8.4M)(4.6M)(7.53M)(1.46M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity375.34M294.96M82.89M22.77M(14.27M)
Total Debt48.08M43.11M38.1M30.57M26.8M
Net Debt(130.79M)(57.34M)(7.1M)(11.35M)5.85M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.